Abstract Library

#3001 Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy

Introduction: PRRT response assessment is performed using RECIST, yet functional assessment using 68Ga-DOTATATE PET/CT and plasma CgA might give additional information about prediction of overall survival (OS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Huizing D, Aalbersberg E, Versleijen M, Tesselaar M, Walraven I,

Keywords: PRRT, RECIST, 68Ga-DOTATATE PET/CT, response,

#2993 Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1

Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: de Mestier L, Dromain C, Lamarca A, La Salvia A, Op de Beeck B,

Keywords: imaging criteria, response evaluation, CT scan,

#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?

Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liberini V

Authors: Liberini V, Rampado O, Gallio E, De Santi B, Ceci F,

Keywords: radiomic, PRRT, NET, SSTR-RADS, NETPET grade, RECIST 1.1 criteria, 68Ga-DOTATOC PET/CT, tumor/spleen ratio, radiomic analysis of 68Ga-DOTATOC PET/CT, radiomic features,

#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,

#2917 Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors

Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Galler M, Schatka I, Buch F, Bluemel S, Jann H,

Keywords: Lu-177-DOTATOC, PRRT, NET, dosimetry, SPECT/CT, Quantification,